Age and sex-adjusted HRs and their 95% CIs for associations of changes in working conditions between phase 1 (2000–2002) and phase 2 (2007) and subsequent psychotropic medication between phase 2 and the end of 2013, the Helsinki Health Study, Finland
| Any psychotropic (N=3587) | Antidepressants (N06A) (N=3660) | Anxiolytics (N05B) (N=3867) | Sedatives and hypnotics (N05C) (N=3808) | |||||||||
| n (cases) | HR | 95% CI | n (cases) | HR | 95% CI | n (cases) | HR | 95% CI | n (cases) | HR | 95% CI | |
| Job control | ||||||||||||
| High–high | 1477 (402) | 0.92 | 0.80 to 1.07 | 1499 (264) | 085 | 0.71 to 1.01 | 1573 (102) | 0.73 | 0.56 to 0.96 | 1559 (245) | 0.97 | 0.81 to 1.17 |
| High–low | 506 (148) | 1.00 | 0.82 to 1.21 | 518 (95) | 0.88 | 0.70 to 1.12 | 542 (43) | 0.89 | 0.63 to 1.27 | 532 (94) | 1.09 | 0.86 to 1.40 |
| Low–high | 417 (117) | 0.95 | 0.77 to 1.18 | 425 (80) | 0.90 | 0.70 to 1.16 | 457 (27) | 0.66 | 0.43 to 1.00 | 449 (91) | 1.29 | 1.00 to 1.65 |
| Low–low | 1187 (341) | 1.00 | Reference | 1218 (244) | 1.00 | Reference | 1295 (113) | 1.00 | Reference | 1268 (205) | 1.00 | Reference |
| Job demands | ||||||||||||
| Low–low | 1188 (304) | 0.82 | 0.71 to 0.96 | 1208 (205) | 0.83 | 0.69 to 1.00 | 1267 (83) | 0.75 | 0.57 to 1.00 | 1254 (185) | 0.83 | 0.68 to 1.01 |
| Low–high | 584 (165) | 0.90 | 0.75 to 1.08 | 598 (117) | 0.91 | 0.73 to 1.14 | 632 (45) | 0.79 | 0.56 to 1.12 | 619 (108) | 0.99 | 0.79 to 1.25 |
| High–low | 601 (169) | 0.90 | 0.75 to 1.08 | 610 (106) | 0.84 | 0.67 to 1.05 | 649 (41) | 0.72 | 0.50 to 1.03 | 639 (110) | 0.96 | 0.77 to 1.21 |
| High–high | 1214 (370) | 1.00 | Reference | 1244 (255) | 1.00 | Reference | 1319 (116) | 1.00 | Reference | 1296 (232) | 1.00 | Reference |
| Physical work load | ||||||||||||
| Low–low | 2351 (633) | 0.85 | 0.72 to 1.02 | 2390 (423) | 0.77 | 0.63 to 0.95 | 2508 (168) | 0.60 | 0.45 to 0.81 | 2480 (382) | 0.82 | 0.66 to 1.03 |
| Low–high | 360 (112) | 0.91 | 0.71 to 1.17 | 371 (78) | 0.90 | 0.68 to 1.20 | 400 (26) | 0.66 | 0.43 to 1.02 | 384 (74) | 1.09 | 0.81 to 1.46 |
| High–low | 359 (104) | 1.00 | 0.78 to 1.27 | 369 (63) | 0.72 | 0.53 to 0.98 | 396 (30) | 0.57 | 0.36 to 0.90 | 398 (80) | 1.03 | 0.76 to 1.39 |
| High–high | 517 (159) | 1.00 | Reference | 530 (119) | 1.00 | Reference | 563 (61) | 1.00 | Reference | 546 (99) | 1.00 | Reference |
Participants with psychotropic medication purchases in question (the medication groups were not mutually exclusive) in 3 months preceding phase 2 were excluded.